Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 6 art units • 8 examiners • 0 of 9 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Creative Medical Technologies Inc. has 9 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 8 distinct examiners and 6 distinct art units, showing a broad examination footprint with concentration across both examiner and art-unit assignments.
VIVLEMORE, TRACY ANN is the busiest examiner, with 2 pending matters. That assignment merits coordinated review, while the remaining workload requires differentiated strategies across the other examination channels.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (11%) |
| §103 only | 1 (11%) |
| Multi-statute (no §101) | 7 (78%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIVLEMORE, TRACY ANN | 2 | 73.0% | +6.4% |
| CANDELARIA, JULIANA IRENE | 1 | 0.0% | +0.0% |
| CONNORS, ALEXANDRA F | 1 | 23.7% | +45.5% |
| LARA, CAROLINE MONSERRAT | 1 | 85.7% | +16.7% |
| DUNN, LINDSAY MICHELLE | 1 | 80.0% | +0.0% |
| NGUYEN, NGHI V | 1 | 53.6% | +50.8% |
| SPENCER, ANDREA LYNNE MORRIS | 1 | 20.0% | +37.5% |
| KIM, TAEYOON | 1 | 51.4% | +52.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18300210 | ENHANCEMENT OF CARTILAGE REGENERATIVE ACTIVITY OF STEM CELL POPULATIONS BASED ON REDUCTION OF INTRA-ARTICULAR CELLULAR MATERIAL | KIM, TAEYOON | 161d overdue |
| 18785305 | Orthopedic Regeneration by Inducible Pluripotent Stem Cell Derived Mesenchymal Stem Cells | CANDELARIA, JULIANA IRENE | — |
| 18785132 | In Vitro and In Vivo Generation of Insulin Producing Cells | CONNORS, ALEXANDRA F | — |
| 18775133 | Creation of Inducible Pluripotent Stem Cell Derived T Regulatory Cells by In Vitro Recapitulation ofThymic Development | LARA, CAROLINE MONSERRAT | — |
| 18483485 | TREATMENT OF DIABETES BY ENHANCEMENT OF PANCREATIC ISLET ENGRAFTMENT THROUGH REGENERATIVE IMMUNE MODULATION | DUNN, LINDSAY MICHELLE | — |
| 18363642 | PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS | NGUYEN, NGHI V | — |
| 18331042 | GENERATION OF CONDITIONED MEDIA FROM INDUCIBLE PLURIPOTENT STEM CELL DERIVED MESENCHYMAL STEM CELLS | SPENCER, ANDREA LYNNE MORRIS | — |
| 18331098 | INDUCIBLE PLURIPOTENT STEM CELL DERIVED REGENERATIVE T CELLS | VIVLEMORE, TRACY ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18300210 | ENHANCEMENT OF CARTILAGE REGENERATIVE ACTIVITY OF STEM CELL POPULATIONS BASED ON REDUCTION OF INTRA-ARTICULAR CELLULAR MATERIAL | KIM, TAEYOON | 161d overdue |
| 18785132 | In Vitro and In Vivo Generation of Insulin Producing Cells | CONNORS, ALEXANDRA F | — |
| 18775133 | Creation of Inducible Pluripotent Stem Cell Derived T Regulatory Cells by In Vitro Recapitulation ofThymic Development | LARA, CAROLINE MONSERRAT | — |
| 18363642 | PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS | NGUYEN, NGHI V | — |
| 18331042 | GENERATION OF CONDITIONED MEDIA FROM INDUCIBLE PLURIPOTENT STEM CELL DERIVED MESENCHYMAL STEM CELLS | SPENCER, ANDREA LYNNE MORRIS | — |
| Art Unit | Apps |
|---|---|
| 1634 | 2 |
| 1631 | 2 |
| 1638 | 2 |
| 1633 | 1 |
| 1644 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18785305 | Orthopedic Regeneration by Inducible Pluripotent Stem Cell Derived Mesenchymal Stem Cells | CANDELARIA, JULIANA IRENE | 1634 | §101§102§112DP | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18785132 | In Vitro and In Vivo Generation of Insulin Producing Cells | CONNORS, ALEXANDRA F | 1634 | §102§103§112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18775133 | Creation of Inducible Pluripotent Stem Cell Derived T Regulatory Cells by In Vitro Recapitulation ofThymic Development | LARA, CAROLINE MONSERRAT | 1633 | §102§103§112 | Non-Final OA | — | Pending | Jul 17, 2024 |
| 18483485 | TREATMENT OF DIABETES BY ENHANCEMENT OF PANCREATIC ISLET ENGRAFTMENT THROUGH REGENERATIVE IMMUNE MODULATION | DUNN, LINDSAY MICHELLE | 1644 | §103§112 | Non-Final OA | — | Pending | Oct 09, 2023 |
| 18363642 | PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS | NGUYEN, NGHI V | 1653 | §102§103§112 | Non-Final OA | — | Pending | Aug 01, 2023 |
| 18331042 | GENERATION OF CONDITIONED MEDIA FROM INDUCIBLE PLURIPOTENT STEM CELL DERIVED MESENCHYMAL STEM CELLS | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103§112 | Non-Final OA | — | Pending | Jun 07, 2023 |
| 18331098 | INDUCIBLE PLURIPOTENT STEM CELL DERIVED REGENERATIVE T CELLS | VIVLEMORE, TRACY ANN | 1638 | §102§103§112 | Non-Final OA | — | Pending | Jun 07, 2023 |
| 18311464 | PROTECTION FROM OVARIAN FAILURE BY LOW DOSE INTERLEUKIN-2 ADMINISTRATION | VIVLEMORE, TRACY ANN | 1638 | §103 | Non-Final OA | 83d | Pending | May 03, 2023 |
| 18300210 | ENHANCEMENT OF CARTILAGE REGENERATIVE ACTIVITY OF STEM CELL POPULATIONS BASED ON REDUCTION OF INTRA-ARTICULAR CELLULAR MATERIAL | KIM, TAEYOON | 1631 | §102§103§112 | Non-Final OA | 161d overdue | Pending | Apr 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCreative Medical Technologies Inc. has 9 pending office actions as of October 2026, spread across 6 art units and 8 examiners.
Tracy Ann Vivlemore has the most, with 2 of Creative Medical Technologies Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
